Gemtuzumab (CD33) - Research Grade Biosimilar
Product Specifications
Background
Gemtuzumab ozogamicin is a recombinant humanized IgG4 kappa antibody which is conjugated with calicheamicin derivative, a cytotoxic antitumor antibiotic isolated from fermentation of Micromonospora echinospora ssp.calichensis.Gemtuzumab ozogamicin has approximately 50% of the antibody loaded with 4-6 moles calicheamicin per mole of antibody Label.The antibody is specifically directed against the CD33 antigen present on leukemic myeloblasts in most patients with acute myeloid leukemia (AML) .By binding to the CD33 antigen on tumors, the cytotoxic agent blocks the growth of cancerous cells and causes cell death.
Swiss Prot
P20138
Immunogen
Humanized / CD33 [Homo sapiens]
Clonality
Recombinant Monoclonal
Conjugation
Unconjugated
Type
Primary Antibodies, Biosimilars
Source
CHO cells
Field of Research
Cancer
Purification
>95%
Concentration
Batch dependent
Buffer
PBS buffer pH7.5
Modification
None
Shipping Conditions
Blue Ice
Storage Conditions
Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8 ˚ C for 1-2 weeks. Store at -20 ˚ C for 12 months. Store at -80 ˚ C for long term storage.
Product Datasheet
https://www.prosci-inc.com/?datasheet_sku=10-081
Fragment
IgG4-kappa
NCBI Organism
Homo sapiens
Other Product Names
CDP-771, CMA-676 (ADC), WAY-CMA-676, gemtuzumab ozogamicin, hP67.6 (naked), hP67.6-calicheamicin (ADC), CD33, CD33
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items